05:23 AM EST, 11/12/2025 (MT Newswires) -- (Updates with the company statement from the first paragraph.)

Novo Nordisk India, a subsidiary of Denmark's Novo Nordisk ( NVO ) , announced a 37% price reduction on Tuesday for its weight management drug, Wegovy, targeting a larger section of overweight and obese people in the country.

For the 0.25 milligram therapy, the company reduced the price to 2,712 Indian rupees ($30.6) from 4,336 rupees.

The price reduction applies to all strengths of Wegovy, which was launched in June in five dose potencies, the company said, while adding that the medication is "indicated for both chronic weight management and reduction in cardiovascular risks."

Shares of Novo Nordisk ( NVO ) rose almost 1% in Wednesday's premarket activity, after closing 7% higher in regular trading on Tuesday.